Codagenix Inc. announced favorable safety and immunogenicity data from a Phase I dose-escalation trial of the company’s single-dose intranasal COVI-VAC vaccine, and London-based pHOXBIO Ltd. reported results from a pivotal phase II/III study of the novel prophylactic nasal spray pHOXWELL.

Artificial Intelligence (AI) is at the forefront of modern technology and has begun to parallel in the world of biotechnology. Many biopharma companies are using AI to drive innovation, enhance their processes and explore new business models.

Swoop, a leader in AI-generated digital audiences for healthcare, announced the release of its newest product offerings that uncover optimal healthcare provider (HCP) influencers for life sciences companies.

Two very exciting areas where Artificial Intelligence (AI) is having an impact on the life sciences landscape are patient stratification and synthetic control arms. Recent data and technology advances are starting to yield compelling results, according to Derek Baird, President North America of Sensyne Health and Commercial Director of SENSE.

Talkatoo, creators of the easy-to-use, efficient and platform-agnostic dictation software for animal health professionals, announced the closing of a new, oversubscribed round of funding led by Klick Ventures.

Real Chemistry, a global health innovation company, and Aktana, a leader in intelligent customer engagement for the global life sciences industry, announced a partnership that will transform commercial strategy, engagement and execution.

Data and AI scientists must strive to eliminate bias from anything that touches patient care.

Combining medical information (MI) and pharmacovigilance (PV) has been shown to drive an array of positive outcomes, including accelerating adverse event intake, improving healthcare professional and patient communications, intelligently connecting enterprise systems and importantly, driving better patient safety. New innovations in connected technologies are finally making it possible to combine elements of these functions in a thoughtful way. However, the change from legacy processes and mindset will be significant and driving employee adoption to see the benefit of these investments will require careful change management. IQVIA’s Annette Williams and Libbie McKenzie explore considerations for leaders looking to combine aspects of their MI and PV functions and how they can effectively roll out this shift to maximize the benefits to their organizations along with patients, providers, and other key stakeholders.

Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.

Hong Kong-based Insilico Medicine closed on a Series C financing round worth $255 million.